Evolent Health (EVH) AI Stock Analysis

• Market Cap: $977.94M
• Dividend Yield: N/A
• Average Volume (3M): 2.10M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 10.24%
• EPS Growth: 2.63%
• Country: US
• Employees: 4,500
• Sector: Healthcare
• Sector Strength: 42
• Industry: Medical - Healthcare Information Services
• EPS (TTM): 0.06
• Shares Outstanding: 117,399,810
• 10 Day Avg. Volume: 1,491,633
• 30 Day Avg. Volume: 2,096,905
• PEG Ratio: -6.50
• Price to Book (P/B): 1.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -173.38
• Enterprise Value/Market Cap: 1.71
• Enterprise Value/Revenue: 0.18
• Enterprise Value/Gross Profit: 5.43
• Enterprise Value/Ebitda: 6.27
• 1Y Price Target: $15.00
• Price Target Upside: 80.07% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8

• Rating: 54 Neutral
• Price Target: $9.00 ▲(8.04%Upside)

Evolent Health demonstrates robust revenue growth and strategic expansions, yet faces challenges in profitability and cash management. Technical indicators suggest bearish trends, and the negative P/E ratio reflects ongoing unprofitability. The positive earnings call provides some optimism but is countered by financial risks and valuation concerns.

Positive Factors

Earnings Performance

The adjusted EPS for 2025 is modeled to be higher than the Street target, indicating confidence in better-than-expected earnings performance.

Profitability

The 2025 adjusted EBITDA estimate for Evolent Health has been slightly increased to align with the guidance midpoint, suggesting an optimistic view on profitability.

Revenue Growth

Specialty Technology & Services revenue is projected to grow by 23% year-over-year in 2025.

Negative Factors

Cost Outlook

The business fell short of the target thresholds on both adjusted EBITDA metrics, reflecting a change in outlook on costs in the back half of the year.

P&L Impact

The moving pieces between the Performance Suite and Technology & Services Suite are impacting P&L.

Performance Suite Revenue

Performance Suite revenue is estimated to decrease by 32% year-over-year in 2025.

Evolent Health Business Overview & Revenue Model

Company Description

Evolent Health (EVH) is a healthcare services company that partners with healthcare providers and payers to drive value-based care transformation. Evolent focuses on helping its clients improve clinical and financial outcomes through its innovative solutions, including population health management, risk adjustment, and value-based specialty care. The company operates primarily in the United States, serving a wide range of healthcare organizations by providing technology-enabled services and integrated solutions to enhance patient care and optimize operational efficiency.

How the Company Makes Money

Evolent Health makes money through a variety of revenue streams centered around its healthcare services and solutions. The company generates revenue by partnering with healthcare providers and payers to implement value-based care models, which often involve long-term contracts and shared savings arrangements. Evolent offers services such as population health management, risk adjustment, and specialty care management, which are typically sold on a subscription basis or through performance-based agreements. Additionally, Evolent may earn fees from consulting services and the implementation of its technology platforms aimed at improving clinical outcomes and reducing costs. Key partnerships with healthcare organizations and insurers play a significant role in its earnings, as they expand Evolent's reach and capability to deliver comprehensive value-based care solutions.

Evolent Health Financial Statement Overview

Summary

Evolent Health is experiencing significant revenue growth, with challenges in profitability due to negative EBIT and net income margins. Improvements in the debt-to-equity ratio and positive operating cash flow indicate a stronger financial position, but ongoing cash utilization issues and negative free cash flow highlight the need for better capital management.

Income Statement

Evolent Health has experienced consistent revenue growth, with a notable increase of 30% from 2022 to 2023 and 2023 to 2024. However, the company is struggling with profitability, as indicated by negative EBIT and net income margins. Despite the growing revenue, the net profit margin remains negative, which poses a challenge for future profitability.

Balance Sheet

The debt-to-equity ratio has improved over time, falling from 0.40 in 2023 to 0.22 in 2024, indicating a stronger equity position. However, the company has negative net income, impacting the return on equity. The equity ratio is relatively stable, suggesting a balanced asset structure. Continued focus on reducing liabilities relative to equity is necessary.

Cash Flow

Operating cash flow turned positive in 2024, but free cash flow remains negative due to high capital expenditures. The operating cash flow to net income ratio has improved, indicating better cash management despite persistent net losses. Free cash flow to net income remains challenging, reflecting ongoing cash utilization issues.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
2.55B	1.96B	1.35B	907.96M	1.02B
	Gross Profit
367.35M	460.47M	316.58M	250.41M	321.06M
	EBIT
-40.48M	-71.21M	-59.84M	30.25M	-37.88M
	EBITDA
84.85M	-24.79M	43.75M	55.66M	-241.38M
	Net Income Common Stockholders
-61.62M	-113.04M	-18.70M	-30.28M	-334.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
163.50M	192.82M	188.20M	266.28M	340.49M
	Total Assets
2.54B	2.68B	1.82B	1.42B	1.37B
	Total Debt
713.67M	644.80M	476.12M	280.47M	359.78M
	Net Debt
609.47M	451.97M	287.92M	14.19M	19.29M
	Total Liabilities
1.54B	1.61B	957.88M	725.83M	750.59M
	Stockholders Equity
1.00B	1.07B	859.42M	693.63M	619.60M
Cash Flow		Free Cash Flow
-6.13M	113.84M	-49.91M	13.76M	-45.70M
	Operating Cash Flow
18.77M	142.58M	-11.55M	38.75M	-16.23M
	Investing Cash Flow
-62.93M	-415.54M	-259.12M	-15.79M	261.07M
	Financing Cash Flow
-565.00K	281.34M	131.54M	-29.55M	-11.86M

Evolent Health Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 8.33
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EVH, the sentiment is Neutral. The current price of 8.33 is above the 20-day moving average (MA) of 8.25, below the 50-day MA of 9.12, and below the 200-day MA of 15.19, indicating a neutral trend. The MACD of -0.36 indicates Negative momentum. The RSI at 47.86 is Neutral, neither overbought nor oversold. The STOCH value of 72.39 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for EVH.

Evolent Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CERT	74 Outperform	$1.91B	―	-0.25%	―	9.37%	95.72%
OMCL	67 Neutral	$1.45B	68.22	1.73%	―	3.00%	―
PHR	58 Neutral	$1.60B	―	-15.97%	―	16.29%	66.01%
EVH	54 Neutral	$977.94M	―	-10.99%	―	10.24%	2.63%
Sector *	54 Neutral	$5.31B	3.28	-45.10%	2.80%	16.76%	0.02%
TDOC	52 Neutral	$1.28B	―	-54.49%	―	-2.54%	-322.03%

Evolent Health Corporate Events

Evolent Health Restructures Board Committees in June 2025

On June 5, 2025, Evolent Health‘s Board of Directors restructured its committees, appointing Brendan Springstubb to both the Audit and Compensation Committees, as part of a cooperation agreement with Engaged Capital. During the 2025 Annual Meeting, stockholders elected ten directors, ratified Deloitte & Touche LLP as the accounting firm, approved executive compensation for 2024, and amended the 2015 Omnibus Incentive Compensation Plan.

The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.

Evolent Health Reaffirms 2025 Revenue and EBITDA Guidance

On June 3, 2025, Evolent Health‘s management will present at the William Blair 45th Annual Growth Stock Conference, reaffirming its 2025 revenue guidance of $2.06 billion to $2.11 billion and Adjusted EBITDA guidance of $135.0 million to $165.0 million. The company also expects to reaffirm its second quarter 2025 revenue guidance of $440.0 million to $470.0 million and Adjusted EBITDA guidance of $33.0 million to $40.0 million, consistent with previous guidance. Evolent Health highlights the challenges in reconciling non-GAAP Adjusted EBITDA to net income due to various adjustments related to non-core operations and other factors.

The most recent analyst rating on (EVH) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on Evolent Health stock, see the EVH Stock Forecast page.

Evolent Health Nominates Shawn Guertin to Board

On April 16, 2025, Diane Holder announced she would not seek re-election to Evolent Health‘s Board of Directors at the upcoming annual meeting on June 5, 2025. Her decision was not due to any disagreement with the company. In response, the Board has nominated Shawn Guertin, a seasoned executive with extensive experience in the healthcare industry, to stand for election. Guertin’s nomination aligns with Evolent’s ongoing efforts to refresh its board with independent directors, aiming to enhance corporate governance and drive shareholder value.